(Total Views: 757)
Posted On: 12/15/2023 5:02:02 PM
Post# of 155138
The bar is pretty low for Glioblastoma, it seems.
Northwest Biotherapeutics was encouraged by their drug DC-Vax L's Phase III test for Glioblastoma. Yet their drug increased median survival by less than three months, and increased survival at 4 years only up to 13 percent. Which means that almost seven of eight patients died within four years.
I hope Leron will do much better. Ohm can probably tell us whether it will.
Here is a paragraph detailing DC-Vax L's Phase III great success:
Northwest Biotherapeutics was encouraged by their drug DC-Vax L's Phase III test for Glioblastoma. Yet their drug increased median survival by less than three months, and increased survival at 4 years only up to 13 percent. Which means that almost seven of eight patients died within four years.
I hope Leron will do much better. Ohm can probably tell us whether it will.
Here is a paragraph detailing DC-Vax L's Phase III great success:
Quote:
In the Phase III trial of DCVax®-L, median Overall Survival (mOS) for newly diagnosed GBM patients (n=232) was 19.3 months from randomization (22.4 months from surgery) with DCVax-L vs. 16.5 months from randomization in the controls (HR=0.80, p=0.002). Survival at 48 months from randomization was 15.7% vs. 9.9%, and at 60 months was 13% vs. 5.7%. For recurrent GBM (n=64), mOS was 13.2 months from relapse vs. 7.8 months (HR = 0.58, p<0.001). Survival at 24 and 30 months post-recurrence was 20.7% vs. 9.6%, and 11.1% vs 5.1%, respectively. In newly diagnosed GBM patients with methylated MGMT, mOS was 30.2 months from randomization (33 months from surgery) with DCVax-L (n=90) vs. 21.3 months in controls (n=199) (HR=0.74, p=0.027).
(8)
(1)
